Navigation Links
ChanTest Develops New Cardiotoxicity and Contractility Assay with Human Stem Cell Cardiomyocytes
Date:5/14/2013

Cleveland, OH (PRWEB) May 14, 2013

Cardiovascular (CV) toxicity is a leading contributor to drug withdrawal and late-stage attrition in the drug discovery process. There is an urgent need for novel in vitro assays that enable earlier and broader testing for CV activity.

The most relevant cells for pre-clinical testing are human cells. Use of these cells has the potential to add significant efficiencies, reduce animal use and decrease the number of dangerous drugs that reach the market.

In response to this need, ChanTest has developed a new assay using ACEA Bioscience’s xCELLigence System (San Diego, CA) and human induced pluripotent stem cell (iPSC) derived cardiomyocytes from Cellular Dynamics International (CDI, Madison, WI). Based on an extensive research program, ChanTest has created several unique algorithms for twitch detection and kinetic analysis, and has concluded an investigation that suggests twitch impedance is a sensitive tool to assess contraction in a relatively high-throughput assay.

The studies concluded that the impedance twitch recordings accurately reflect key elements of contraction, thus allowing the study of drugs that affect excitation-contraction coupling and the contractile apparatus. In addition, since impedance signals can be recorded over long periods of time, deleterious long-term drug effects, such as those commonly observed for oncology drugs, can be easily evaluated with this label-free procedure. Therefore, the new ChanTest assay, applied to iPSC derived cardiomyocytes, offers an effective non-invasive screen for the cardiotoxicity and contractility.

"We listened to the requests of the pharmaceutical industry for a human cell based cardiotox and contractility assay," explained Chris Mathes, Ph.D., Chief Commercial Officer at ChanTest. "This new assay fulfills that need by combining ChanTest expertise with state-of-the art technology from ACEA and iPSC cardiomyocytes from CDI."

To learn more about the new ChanTest assay using ACEA Bioscience’s xCELLigence system, click here.

FURTHER INFORMATION

ChanTest
14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
1-216-332-1665 Tel
1-216-332-1706 Fax
info(at)chantest(dot)com

Contact for Media Inquiries:

Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer
cmathes(at)chantest(dot)com
http://www.chantest.com

About ChanTest® – The Ion Channel Expert

ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 500 global pharmaceutical and biotechnology companies, and partners with them to speed the drug development process for the release of better, safer drugs.

ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and nonclinical cardiac risk assessment service portfolio is the most comprehensive commercially available today.

Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past eight years. ChanTest is based in Cleveland, Ohio.

Visit http://www.chantest.com to learn more about what we do.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10724621.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
2. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
3. ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
4. NASA develops super-black material that absorbs light across multiple wavelength bands
5. UCLA team develops highly efficient method for creating flexible, transparent electrodes
6. Ecology Coatings Develops Coatings Safe for Direct Contact with Food Products
7. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
8. Harvards Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses
9. College Chairman And Prolific Inventor Develops Life-Saving, Real-Time Diagnostic Technologies
10. Union Equity, Inc.s Wholly Owned Subsidiary Develops Cream that Aids in Soothing the Symptoms of Chemotherapy
11. Medi-Solve Coatings Develops Masking Process for Medical Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus ... justice technology solutions for public safety, investigation, corrections ... the prisons involved, it has secured the final ... (DOC) facilities for Managed Access Systems (MAS) installed. ... additional facilities to be installed by October, 2016. ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/9/2016)... TURKU, Finland , June 9, 2016 ... French National Police deploy Teleste,s video security solution to ensure ... France during the major tournament ... and data communications systems and services, announced today that its ... Police Prefecture to back up public safety across ...
Breaking Biology News(10 mins):